Rituximab/bendamustine/cytarabine for transplant-eligible patients with mantle cell lymphoma: A retrospective study.
Adult
Humans
Lymphoma, Mantle-Cell
/ drug therapy
Rituximab
/ adverse effects
Retrospective Studies
Bendamustine Hydrochloride
/ adverse effects
Hematopoietic Stem Cell Transplantation
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Transplantation, Autologous
Cyclophosphamide
/ adverse effects
Prednisone
/ adverse effects
Vincristine
/ adverse effects
Cytarabine
/ adverse effects
Doxorubicin
/ adverse effects
effective and safe
induction therapy
mantle cell lymphoma
rituximab/bendamustine/cytarabine
transplant eligibility
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
05
05
2023
received:
25
03
2023
accepted:
08
05
2023
medline:
20
6
2023
pubmed:
18
5
2023
entrez:
18
5
2023
Statut:
ppublish
Résumé
Mantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies. Herein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, bendamustine, and cytarabine (R-BAC) at Toranomon Hospital between November 2016 and February 2022. Although one patient discontinued R-BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high-dose chemotherapy and autologous stem cell transplantation, and maintained complete remission with a median follow-up of 15 months. Hematological adverse events (AEs) occurred in all patients; however, none developed documented infection. There were also no fatal non-hematological AEs specific to R-BAC. R-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma.
Sections du résumé
BACKGROUND
Mantle cell lymphoma is considered an aggressive B-cell lymphoma. The optimal induction regimen remains controversial as no randomized controlled trial has compared the efficacy of different induction therapies.
METHOD
Herein, we performed a retrospective analysis of the clinical characteristics of 10 patients who received induction treatment consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and rituximab, bendamustine, and cytarabine (R-BAC) at Toranomon Hospital between November 2016 and February 2022.
RESULT
Although one patient discontinued R-BAC therapy due to a rash, the other nine completed the scheduled chemotherapy. All patients achieved complete response, underwent high-dose chemotherapy and autologous stem cell transplantation, and maintained complete remission with a median follow-up of 15 months. Hematological adverse events (AEs) occurred in all patients; however, none developed documented infection. There were also no fatal non-hematological AEs specific to R-BAC.
CONCLUSION
R-CHOP/R-BAC may be a good induction therapy for transplant-eligible patients with mantle cell lymphoma.
Identifiants
pubmed: 37199050
doi: 10.1002/cam4.6114
pmc: PMC10278520
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Vincristine
5J49Q6B70F
Cytarabine
04079A1RDZ
Doxorubicin
80168379AG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12548-12552Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Blood Cells Mol Dis. 2012 Jan 15;48(1):68-75
pubmed: 22036761
Cancer Sci. 2018 Sep;109(9):2830-2840
pubmed: 29957865
Lancet Oncol. 2017 Aug;18(8):e445-e456
pubmed: 28759384
Blood. 2008 Oct 1;112(7):2687-93
pubmed: 18625886
Blood Adv. 2020 Mar 10;4(5):858-867
pubmed: 32126141
Leukemia. 2002 Apr;16(4):587-93
pubmed: 11960337
Cancer Med. 2023 Jun;12(11):12548-12552
pubmed: 37199050
Blood. 2005 Apr 1;105(7):2677-84
pubmed: 15591112
Lancet. 2016 Aug 6;388(10044):565-75
pubmed: 27313086
Br J Haematol. 2016 Apr;173(1):89-95
pubmed: 26729345
Br J Haematol. 2018 Jul;182(1):46-62
pubmed: 29767454
Lancet Haematol. 2017 Jan;4(1):e15-e23
pubmed: 27927586
J Clin Oncol. 2013 Apr 10;31(11):1442-9
pubmed: 23401442
Br J Haematol. 2012 Feb;156(3):346-53
pubmed: 22145911
Cancers (Basel). 2021 Dec 03;13(23):
pubmed: 34885198
Blood. 2013 Jan 3;121(1):48-53
pubmed: 22718839
Blood Adv. 2020 Aug 11;4(15):3486-3494
pubmed: 32735654
EJHaem. 2020 Oct 03;1(2):498-506
pubmed: 35845008
Ann Hematol. 2016 Sep;95(9):1513-9
pubmed: 27365141
J Clin Oncol. 1998 Dec;16(12):3803-9
pubmed: 9850025
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727